| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Department of Endocrinology and Metabolism, Orthopedic and Traumatology, Occupational Medicine, University of Pisa; 2 Pathologic Anatomy Service, S.Chiara Hospital, Pisa, Italy; 3 Pathology Unit, Department of Oncology, Azienda Sanitaria Ospedaliera, Alessandria, Italy; 4 National Cancer Research Institute, Unit of Environmental Epidemiology, Genoa, Italy; 5 Section of Histology and Embryology,Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy; 6 S.Pietro e Paolo Hospital, Borgosesia, Italy; and 7 S.Maugeri Foundation Institute for Research and Care, Pavia, Italy
Requests for reprints: Alfonso Cristaudo, Occupational Preventive Medicine, AOP, Via S.Maria 110, 56100 Pisa, Italy. Phone: 39-50993820; Fax: 39-50993822; E-mail: a.cristaudo{at}med.unipi.it.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
To test our hypothesis that SV40 contributes to mesothelioma pathogenesis only as a cofactor, among asbestos-exposed individuals, we conducted a molecular epidemiologic case-control study to retrospectively assess the risk of developing MM among people exposed to asbestos and infected with SV40.
| Materials and Methods |
|---|
|
|
|---|
The histologic examination and classification of tumors were done according to WHO criteria (The New WHO/International Association for the Study of Lung Cancer Histologic Classification of Lung and Pleural Tumors, 1999). The diagnosis of MM was achieved through cytologic assessment of pleural effusion specimens or histologic examination of pleural biopsies obtained through thoracoscopy or thoracotomy. All MM biopses studied contained a vast majority of malignant cells and minimal stromal/inflammatory or otherwise nonmalignant cells. Light microscopy examination was always supplemented by immunochemistry using a standard battery of primary antibodies (calretinin, cytokeratin, carcinoembryonic antigen, BerEP-a, and CD15). All final diagnoses of mesothelioma were supported by both clinical and pathologic evidence. Histologically, MM samples were composed of 16 epithelioid, 2 mixed, and 1 sarcomatoid histotype. The diagnosis of BU was done according to WHO criteria.
A written informed consent was obtained from all patients before enrollment and study protocol was approved by the ethics committee of the participating institution.
Personal interviews were done on all subjects by trained personnel using the questionnaire proposed by the Istituto Superiore per la Prevenzione e la Sicurezza del Lavoro (the Italian National Institute for Health and Safety in work places) and used by the National MM Registry (ReNaM), which is the result of implementation at a national level of European Community directive 83/477/EC. Interviewers were blinded to SV40 status and those interviewed were blinded to their case-control status. Data on the tumor, history of past illnesses, demographic status, smoking habits, diet, alcohol consumption, as well as a detailed work history, and any environmental source of asbestos exposure were gathered. The adopted definition of exposure is the one proposed by the ReNaM. According to ReNaM reference guidelines, we classified all cases and controls in patients with occupational or environmental exposure to asbestos, with no sufficient data for classification, or with no evidence at all of any asbestos exposure. Still, according to ReNaM criteria, the classification of occupational exposure set three levels of probability (ascertained, probable, possible). This made it feasible to classify also all those situations in which the interviewees had not explicitly declared to have been exposed because either the composition of materials or products used during their working life was not perfectly known or information was not substantiated by details useful to define the exposure.
DNA purification. Sections from formalin-fixed, paraffin-embedded tissues were extracted using a commercial kit (Qiagen, Milan, Italy) following the manufacturer's instructions.
PCR and filter hybridization. SV40 DNA from 776 (Sigma, Milan, Italy) strain was used as control in PCR amplification. Each DNA sample was first tested for suitability for PCR by amplification of p53 gene sequences, exons 7 to 8 (Table 1). Only positive samples were further investigated for amplification of SV40 sequences. All experiments were carried out at the Department of Endocrinology and Occupational Medicine, University of Pisa. All available DNA was analyzed for the presence of SV40 DNA in triplicate, and the results were consistently reproduced. To avoid PCR contaminations, the following precautions were carefully taken. Pre- and post-PCR activities were done in separate rooms using dedicated lab tools and supplies. All reagents for both DNA extraction and PCR analysis were exclusively used for the experiments of this study. Only filter tips were used.
|
DNA was amplified for 45 cycles in a total volume of 100 µL containing 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2, 200 µmol/L deoxynucleotide triphosphate, 50 pmol of each primer, and 1 unit of Taq DNA Polymerase (Amersham Pharmacia Biotech, Milan, Italy). The amount of DNA included per reaction volume ranged from 100 to 350 ng. Primers, oligoprobes, annealing temperatures, and PCR product size are reported in Table 1. Ten microliters of each PCR reaction were loaded on 2% agarose gel and electrophoresed in 1x TAE buffer [40 mmol/L Tris acetate and 1 mmol/L EDTA (pH 8)], stained by ethidium bromide, and photographed. DNA was transferred to nylon membranes and cross-linked to filter by UV irradiation. All filters were hybridized to SV40-specific internal oligoprobes (Table 1) at 42°C in 5x SSC (20x SSC: 3 mol/L NaCl, 0.3 mol/L Na citrate), 0.1% SDS, block solution, and 0.5% dextran sulfate (Amersham Pharmacia Biotech). Oligoprobes were 3' end-labeled using the ECL labeling kit and revealed by a chemiluminescent reagent (Amersham Pharmacia Biotech). The stringency of the final wash was adjusted according to the melting temperature. Filters were exposed to X-ray films (Kodak, Rochester, NY) for 15 to 60 minutes.
The univariate relation of each independent variable to the groups under study was examined using the
2 test. Odds ratios (OR) and 95% confidence intervals (95% CI) for the association between MM and SV40 or asbestos were calculated.
| Results |
|---|
|
|
|---|
|
|
Assessing the association between MM and the different combination of SV40 Tag/asbestos, we observed a trend of ORs similar to the one analyzed using primers specific to RReg, although correspondent ORs were smaller. In any case, the association between MM and the concurrent presence of both SV40 Tag and asbestos was still positive (data not shown).
| Discussion |
|---|
|
|
|---|
We found that 33.3% of BU samples contained SV40 RReg sequences. This is, to the best of our knowledge, the first time this type of cancer has been analyzed for the presence of SV40, and there is no immediate or simple explanation for this. We know that, thus far, SV40 DNA has been found in different kind of tumors with a prevalence of virus positivity ranging considerably among different cancers (12). Obviously, finding viral DNA in a minor portion of a limited number of tumor samples does not make it possible to substantiate a causal relationship. To date, there is too little information about this topic to speculate on the role of SV40 in this kind of tumor. However, this unexpected 33.3% of positivity for SV40 DNA among controls might have determined an underestimation of the association between SV40 alone and MM in the population under investigation. In conclusion, our data suggest that SV40 alone may not be able to cause MM in humans, but that it strongly increases the carcinogenic effect of asbestos.
The same conclusions can be drawn considering results (not shown) obtained from the analysis of the association between MM and the different combination of SV40 Tag and asbestos. Once again, the presence of Tag in the absence of asbestos history is not associated with MM, whereas the presence of Tag increases the strength of the association between asbestos and MM. Nevertheless, considering the combinations with positive Tag sequences, ORs were smaller than the ones obtained using RReg sequences as marker of SV40 presence.
To date, no epidemiologic data have been provided supporting the observation that asbestos and SV40 are cocarcinogens in vitro. Recently, some authors (1, 12) have proposed an in vitro model of pathogenic interaction involving the two factors, which is schematically reported.
Asbestos fibers are reported to favor mesothelial cell transformation as a result of several important activities, such as extracellular signal-regulated kinase activity stimulation and epidermal growth factor receptor autophosphorylation, leading to subsequent expression of the proto-oncogenes and AP-1 family members, c-fos, and fra-1 activation (13). Besides, asbestos fibers can determine direct chromosomal breaking and, most important, can cause mononuclear phagocytes to release mutagenic reactive oxygen species resulting in DNA damage and DNA repair pathway activation (13). If DNA repair is not properly accomplished, damaged cells normally undergo apoptosis but occasionally may continue dividing with consequent accumulation of additional mutations. In vitro, the coexistence of other cofactors may allow these cells to overcome apoptotic pathways more efficiently. SV40 may block p53/pRb proteinrelated apoptotic pathways (14). SV40 also stimulates the expression of some cell growth regulators, such as insulin-like growth factor-I, hepatocyte growth factor, and VEGF, and induces the activation of AP-1, Notch-1, and telomerase (15, 16, 3). All these activities may extend the lifetime of damaged mesothelial cells that may divide and accumulate DNA mutations and chromosomal alterations. Consistently, with this hypothesis, Bocchetta et al. (17) reported that although focus formation was not observed in cultured mesothelial cells treated with either crocidolite fibers alone or transfected with plasmids containing only SV40 Tag, a high number of foci developed when mesothelial cells were at the same time treated with both asbestos and plasmid containing SV40 Tag.
Moreover, the well-known immunosuppressive effects of asbestos could allow SV40 to escape host immunologic defense, preventing immune lysis of Tag-positive cells (reviewed in ref. 1).
A recent report suggested that plasmid contamination may account for some of the positive results for SV40 reported in the literature (18). In fact, most sets of primers frequently used in previously published PCR-based studies amplify a region of the viral DNA coding for the Tag exon 2, which is within a 614 nucleotide portion of SV40 present in up to 80 common laboratory vectors. We tested our specimens with a set of primers that amplify a tract of the Sv40 RReg, which is included in two plasmids only, pSVL and pEUK-C1 (http://www.ncbi.nlm.nih.gov/BLAST). We chose these primers to reduce the risk of plasmid contamination, a concern supported by the recent findings of Lopez-Rios et al. (18), who also advised the use of "low-risk primers," such as ours, to test for SV40 sequences in human tumors. Moreover, the two plasmids indicated above were never used in our laboratory, further decreasing the risk of contamination. The fact that all of our negative controls that were handled in parallel with the mesothelioma biopsies at all steps of the procedure (from DNA extraction to the Southern blotting) tested repeatedly negative supported the reliability of our results and ruled out the possibility of laboratory artifacts, such as contamination. Concerning the broader issue of PCR-plasmid contamination raised by Lopez-Rios et al., this is an issue that must be considered by all researchers testing for SV40 in human tumors. Careful precautions and rigorous controls, such as those we used, should always be implemented. However, this risk should not be brought out of proportion. There are over 70 publications from many different laboratories that have reported the presence of SV40 in human mesotheliomas and other cancers. PCR and many other technical approacheselectron microscopy, Western and Northern blotting, immunostaining and immunoprecipitation, in situ hybridization, viral rescue from human biopsies of SV40 strains never detected in laboratory, etc.have been used to validate these findings. It is unlikely that so many laboratories using so many different techniques would be all wrong and that the results would always be error in detecting SV40. Moreover, the detection of SV40 in human cancers has undergone a very critical scrutiny by three independent review panels and all three concluded that SV40 was present in human cancers (12, 19, 20).
In conclusion, our data confirm the presence of SV40 in some mesotheliomas, confirm the reliability of PCR to detect SV40 when stringent precautions to prevent and detect contamination are taken, and provide, for the first time, epidemiologic evidence that support the notion that SV40 and asbestos are cocarcinogens in the pathogenesis of mesothelioma. Furthermore, our findings suggest that detection of SV40 among a cohort of individuals exposed to asbestos could represent a useful marker to identify those at higher risk for MM. This subgroup of high-risk individuals could be closely monitored for early detection and possibly curative surgical excision.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank the Occupational-Environmental Epidemiology Unit, Center for Study and Prevention of Cancer, Florence, Italy, for scientific cooperation.
| Footnotes |
|---|
Received 7/ 2/04. Revised 12/13/04. Accepted 2/17/05.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Sartore-Bianchi, F. Gasparri, A. Galvani, L. Nici, J. W. Darnowski, D. Barbone, D. A. Fennell, G. Gaudino, C. Porta, and L. Mutti Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma Clin. Cancer Res., October 1, 2007; 13(19): 5942 - 5951. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Comar, C. Rizzardi, R. de Zotti, M. Melato, M. Bovenzi, J. S. Butel, and C. Campello SV40 Multiple Tissue Infection and Asbestos Exposure in a Hyperendemic Area for Malignant Mesothelioma Cancer Res., September 15, 2007; 67(18): 8456 - 8459. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cristaudo, R. Foddis, A. Vivaldi, G. Guglielmi, N. Dipalma, R. Filiberti, M. Neri, M. Ceppi, M. Paganuzzi, G. P. Ivaldi, et al. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer Clin. Cancer Res., September 1, 2007; 13(17): 5076 - 5081. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Robinson, I. van Bruggen, A. Segal, M. Dunham, A. Sherwood, F. Koentgen, B. W.S. Robinson, and R. A. Lake A Novel SV40 TAg Transgenic Model of Asbestos-Induced Mesothelioma: Malignant Transformation Is Dose Dependent. Cancer Res., November 15, 2006; 66(22): 10786 - 10794. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kroczynska, R. Cutrone, M. Bocchetta, H. Yang, A. G. Elmishad, P. Vacek, M. Ramos-Nino, B. T. Mossman, H. I. Pass, and M. Carbone Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters PNAS, September 19, 2006; 103(38): 14128 - 14133. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Poulin and J. A. DeCaprio Is There a Role for SV40 in Human Cancer? J. Clin. Oncol., September 10, 2006; 24(26): 4356 - 4365. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cutrone, J. Lednicky, G. Dunn, P. Rizzo, M. Bocchetta, K. Chumakov, P. Minor, and M. Carbone Some Oral Poliovirus Vaccines Were Contaminated with Infectious SV40 after 1961 Cancer Res., November 15, 2005; 65(22): 10273 - 10279. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carbone, M. A. Rdzanek, J. J. Rudzinski, M. A. De Marco, M. Bocchetta, M. Ramos Nino, B. Mossman, and H. I. Pass SV40 Detection in Human Tumor Specimens Cancer Res., November 1, 2005; 65(21): 10120 - 10121. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |